Thirty-year experience in preventing haemoglobinopathies in Greece: Achievements and potentials for optimisation

European Journal of Haematology

Volumn 90, Issue 4, 2013, Pages 313-322

  Ladis, Vassilis ^a,b   Karagiorga Lagana, Markissia ^a,c   Tsatra, Ioanna ^a,d   Chouliaras, Giorgos ^b,e  

^a Department of Haemoglobinopathies   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

thalassaemia major; Greece; Haemoglobinopathies; Prevention programme; Sickle cell disease

Indexed keywords

ARTICLE; BIRTH RATE; COST EFFECTIVENESS ANALYSIS; GENETIC COUNSELING; GREECE; HEALTH SURVEY; HUMAN; INCIDENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; THALASSEMIA MAJOR;

AFRICA; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; EMIGRATION AND IMMIGRATION; GENETIC COUNSELING; GREECE; HEMOGLOBINOPATHIES; HETEROZYGOTE DETECTION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT, NEWBORN; NATIONAL HEALTH PROGRAMS;

EID: 84875241429     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12076     Document Type: Article

References (29)

1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001;79:704-12.
2. Kattamis C. The management of thalassaemia. Present and future. Paediatriki 2000;63:88-92.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004 Oct;89:1187-93.
4. Ladis V, Chouliaras G, Berdoukas V, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Kattamis A, Karagiorga-Lagana M. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol 2011 Apr;86:332-8.
5. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006 May 1;107:3733-7.
6. Chouliaras GL, Kattamis A, Berdoukas V, Gotsis ED, Mavrogeni S, Ladis V. Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction. Br J Haematol 2010 Nov;151:397-401.
7. Loukopoulos D. Current status of thalassemia and the sickle cell syndromes in Greece. Semin Hematol 1996 Jan;33:76-86.
8. Ballardini E, Tarocco A, Marsella M, et al. Universal neonatal screening for sickle cell disease and other haemoglobinopathies in Ferrara, Italy. Blood Transfus 2012; doi: 10.2450/2012.0030-12.
9. Bianco I, Graziani B, Lerone M, Ponzini D, Aliquo MC, Foglietta E. Updated results of the thalassaemia prevention programme carried out in Latium. J Med Genet 1989 Oct;26:667.
10. Voskaridou E, Ladis V, Kattamis A, et al. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol 2012 Sep;91:1451-8.
11. Spanos T, Kattamis C, Kyriopoulos J, Karageorga M, Ladis V, Hatziliami A, Pantelakis S, Matsaniotis N. Aspects economiques du traitement des syndromes thalassémiques. Journal d'Economie Médicale 1988;6:369-83.
12. Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz EA. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen 1998;5:120-6.
13. Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol BO. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes 2010;3:29.
14. Ostrowsky JT, Lippman A, Scriver CR. Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health 1985 Jul;75:732-6.
15. Van Delft P, Lenters E, Bakker-Verweij M, de Korte M, Baylan U, Harteveld CL, Giordano PC. Evaluating five dedicated automatic devices for haemoglobinopathy diagnostics in multi-ethnic populations. Int J Lab Hematol 2009 Oct;31:484-95.
16. Harteveld CL, Ponjee G, Bakker-Verweij M, Arkesteijn SG, Phylipsen M, Giordano PC. Hb Haaglanden: a new nonsickling beta7Glu>Val variant. Consequences for basic diagnostics, screening, and risk assessment when dealing with HbS-like variants. Int J Lab Hematol 2012 Oct;34:551-5.
17. Tzetis M, Traeger-Synodinos J, Kanavakis E, Metaxotou-Mavromati A, Kattamis C. The molecular basis of normal HbA2 (type 2) beta-thalassemia in Greece. Hematol Pathol 1994;8:25-34.
18. Stephens AD, Angastiniotis M, Baysal E, Chan V, Fucharoen S, Giordano PC, Hoyer JD, Mosca A, Wild B. ICSH recommendations for the measurement of haemoglobin A2. Int J Lab Hematol 2012 Feb;34:1-13.
19. Kalokairinou EM. The experience of beta-thalassaemia and its prevention in Cyprus. Med Law 2008 Dec;27:825-41.
20. Toni-Uebari TK, Inusa BP. The role of religious leaders and faith organisations in haemoglobinopathies: a review. BMC Blood Disord 2009;9:6.
21. Angastiniotis MA, Hadjiminas MG. Prevention of thalassaemia in Cyprus. Lancet 1981 Feb 14;1:369-71.
22. Kolnagou A, Kontoghiorghes GJ. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. Hemoglobin 2009;33:287-95.
23. Bozkurt G. Results from the north cyprus thalassemia prevention program. Hemoglobin 2007;31:257-64.
24. Cao A, Rosatelli C, Pirastu M, Galanello R. Thalassemias in Sardinia: molecular pathology, phenotype-genotype correlation, and prevention. Am J Pediatr Hematol Oncol 1991Summer;13(2):179-88.
25. Khorasani G, Kosaryan M, Vahidshahi K, Shakeri S, Nasehi MM. Results of the national program for prevention of beta-thalassemia major in the Iranian Province of Mazandaran. Hemoglobin 2008;32:263-71.
26. Chern JP, Lin KH, Su YN, Lu MY, Jou ST, Lin DT, Wang SC, Lin KS. Impact of a national beta-thalassemia carrier screening program on the birth rate of thalassemia major. Pediatr Blood Cancer 2006 Jan;46:72-6.
27. Modell B, Khan M, Darlison M, King A, Layton M, Old J, Petrou M, Varnavides L. A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ 2001;79:1006-13.
28. Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. Eur J Haematol 2009 May;82:381-7.
29. Chouliaras G, Berdoukas V, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Karagiorga-Lagana M. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging 2011 Jul;34:56-9.